# A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

> **NCT04412174** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hebei Yanda Ludaopei Hospital** · enrollment: 18 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** GC022F

## Key facts

- **NCT ID:** NCT04412174
- **Lead sponsor:** Hebei Yanda Ludaopei Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412174, "A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04412174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*